W
WAVEMAN · COMPANY
PHIO · Phio Pharmaceuticals Corp.
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475
← ALL COMPANIES

PHIO

Phio Pharmaceuticals Corp.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001533040
C-SUITE BUYING · 1☆ WATCH
INSIDER NET · 180D
$37.6K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
2
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
9
13F, latest reported quarter
REVENUE GROWTH
-100.0%
XBRL, annual
NET MARGIN
-
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net +$37.6K over 180 days
+$37.6K over 90 days
more than 71% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
9 funds added or opened last quarter
below 86% of Pharma & Biotech
REVENUE
-100.0% year over year
the lowest in Pharma & Biotech
MARGIN
no margin: this company reports no revenue to divide by
BUYBACKS
no share repurchases reported
SHORT
2.5% of shares outstanding short · 1.0 days to cover · settled 2026-07-31
below 60% of Pharma & Biotech
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -47.6%
-47.6%12M
-60%-34%-9%+17%2025-092025-102025-122026-032026-052026-072026-09 2026-08-19 · Plott Ronald Todd bought $17.1K2026-08-18 · Bitterman Robert J bought $10.6K2026-06-26 · Bitterman Robert J bought $9.9K2025-11-18 · Bitterman Robert J bought $6.3K2025-11-21 · Bitterman Robert J bought $5.7K2025-12-31 · Bitterman Robert J bought $5.2K2025-12-23 · Bitterman Robert J bought $5.1K
INSIDER BUY
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders are net buyers of their own stock.
The record shows a net $37.6K bought by insiders over 180 days, 9 funds added last quarter. Every figure is a federal filing, dated the day it became public.
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Phio Pharmaceuticals Corp. insiders bought a net $37.6K of stock across 28 Form 4 purchases and sales, with 2 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER
FILED
SHARES
VALUE
Plott Ronald Todd
Director
BUY
2026-08-19
15,000.0
$17.1K
Bitterman Robert J
Chairman, Pres. & CEO
BUY
2026-08-18
10,000.0
$10.6K
Bitterman Robert J
Chairman, Pres. & CEO
BUY
2026-06-26
10,000.0
$9.9K
Bitterman Robert J
Chairman, Pres. & CEO
BUY
2025-12-31
5,000.0
$5.2K
Bitterman Robert J
Chairman, Pres. & CEO
BUY
2025-12-23
5,000.0
$5.1K
28 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 23 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
JANE STREET GROUP, LLC
117,755.0 sh
$120.7K
GEODE CAPITAL MANAGEMENT, LLC
114,574.0 sh
$117.4K
VANGUARD CAPITAL MANAGEMENT LLC
94,262.0 sh
$96.6K
NOMURA ASSET MANAGEMENT INTERNATIONAL INC.
50,000.0 sh
$51.0K
Cetera Investment Advisers
47,500.0 sh
$48.7K
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Nomura Healthcare Fund
$61.0K POSITION · AS OF 2026-03-31
0.0%
Fidelity Extended Market Index Fund
$66.2K POSITION · AS OF 2026-02-28
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$97.4K POSITION · AS OF 2026-03-31
0.0%
Fidelity Total Market Index Fund
$15.1K POSITION · AS OF 2026-02-28
0.0%
Fidelity Series Total Market Index Fund
$9.5K POSITION · AS OF 2026-02-28
0.0%
Blackstone Alternative Multi-Strategy Fund
$5 POSITION · AS OF 2026-03-31
0.0%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 1 registered trials, 1 still enrolling or running — a status change here is dated weeks before the press release
1
Phase 1
1 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Executive pay vs shareholder return · Robert M. Infarinato
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2025
$1.2M
$886.0K
$599.7K
-81%
2024
$387.0K
$384.5K
$105.2K
-77%
2023
$437.9K
$379.4K
-94%
2022
$109.4K
$94.7K
-86%
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
OPERATING INCOME$-9.2M$-7.4M$-10.8M$-11.5M
NET INCOME$-8.7M$-7.2M$-10.8M$-11.5M
EPS (DILUTED)-9.08-46.76-10.10
OPERATING CASH FLOW$-8.0M$-7.1M$-10.7M$-12.1M
CASH$21.0M$5.4M$8.5M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-05 ALL SYSTEMS LIVE FOR MACHINES →